Skip to content
CancerIndex

Publication

Molecular reprogramming in cutaneous melanoma: the central role of G9a and EZH2 methyltransferase inhibitors in tumor plasticity, immune evasion, and therapeutic resistance.

Melissa Yoshimi Sakamoto Maeda Nisimoto, Daniel Arcuschin de Oliveira, Heitor Raia Bottura, Wagner Robson Germano Sousa, Gabrielle do Nascimento Sividanes, Amanda Fáris Marques, Jaciara Moreira Sodré Hunnicutt, Alexandre Giannecchini Romagnolo, Maria Clara Ferreira Vivi, Beatriz Linhares Gorini, Francisco Macedo Paschoal, Miguel Sabino Neto, Miriam Galvonas Jasiulionis, Luciana Cavalheiro Marti, Renato Santos de Oliveira Filho

Frontiers in pharmacologyJan 1, 2026PMID 42756612doi:10.3389/fphar.2026.1879451 PMC13583915Journal ArticleReviewpubmedProvenance
Source
PubMed
Retrieved
Sep 30, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260930-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Cutaneous melanoma remains a leading cause of skin cancer-related mortality despite significant therapeutic advances, with treatment resistance and immune evasion representing major clinical challenges. Epigenetic dysregulation, particularly through the histone methyltransferases G9a (EHMT2) and…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.